4.7 Article

Magnetically Assisted Drug Delivery of Topical Eye Drops Maintains Retinal Function In Vivo in Mice

Journal

PHARMACEUTICS
Volume 13, Issue 10, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics13101650

Keywords

magnetic targeting; non-invasive; topical drug delivery; magnetic nanoparticles; retinal degeneration; Bardet Biedl syndrome; unfolded protein response; small drug molecules

Funding

  1. European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant [722717]

Ask authors/readers for more resources

The study presents the development of a non-invasive, magnetic nanoparticle-based drug delivery system for the treatment of retinal degeneration in BBS, demonstrating successful targeting of photoreceptors in vivo after topical administration. The magnetic drug targeting approach showed beneficial biological effects by maintaining light detection in Bbs(-/-) mice (KO), offering potential for expanding treatment options for various retinal degenerations and other ocular diseases.
Barded-Biedl syndrome (BBS) is a rare genetic disorder with an unmet medical need for retinal degeneration. Small-molecule drugs were previously identified to slow down the apoptosis of photoreceptors in BBS mouse models. Clinical translation was not practical due to the necessity of repetitive invasive intravitreal injections for pediatric populations. Non-invasive methods of retinal drug targeting are a prerequisite for acceptable adaptation to the targeted pediatric patient population. Here, we present the development and functional testing of a non-invasive, topical, magnetically assisted delivery system, harnessing the ability of magnetic nanoparticles (MNPs) to cargo two drugs (guanabenz and valproic acid) with anti-unfolded protein response (UPR) properties towards the retina. Using magnetic resonance imaging (MRI), we showed the MNPs' presence in the retina of Bbs wild-type mice, and their photoreceptor localization was validated using transmission electron microscopy (TEM). Subsequent electroretinogram recordings (ERGs) demonstrated that we achieved beneficial biological effects with the magnetically assisted treatment translating the maintained light detection in Bbs(-/-) mice (KO). To our knowledge, this is the first demonstration of efficient magnetic drug targeting in the photoreceptors in vivo after topical administration. This non-invasive, needle-free technology expands the application of SMDs for the treatment of a vast spectrum of retinal degenerations and other ocular diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available